16:10 EDT Neuphoria Therapeutics (NEUP) Inc trading halted, news pending
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- H.C. Wainwright biotech analysts hold an analyst/industry conference call
- Neuphoria Therapeutics: Strong Cash Position and Promising Pipeline Drive Buy Rating
- Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
- Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial
- Neuphoria Therapeutics initiated with a Buy at Lucid Capital